Completed production of pilot batch

We are pleased to report the following information we received from Bloomsbury Genetics:

“In May, Cure INAD UK has provided Bloomsbury Genetic Therapies Limited with a grant of £7,500 to advance/initiate manufacturing activities of their gene therapy candidate (BGT-INAD).

The company is pleased to announce that production of a pilot batch of BGT-INAD has been successfully completed by their selected contract manufacturer. This material will be used to complete further preclinical development activities currently underway in collaboration with their colleagues from UCL (University College London).”

They also provide hope for ANAD and PLA2G6 related dystonia-parkinsonism families:

“If we can demonstrate that BGT-INAD is a safe and efficacious therapeutic option for INAD patients, it is very much our intent to find a way to bring it to patients suffering from other PLA2G6-associated disorders such as ANAD and PLA2G6-related dystonia-parkinsonism, where we would also hope to achieve a potentially curative effect.”